A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer von Willett, C. G, Duda, Dan Gabriel, Ancukiewicz, M, Shah, M, Czito, B. G, Bentley, R, Poleski, M, Fujita, H, Lauwers, Gregory Y, Carroll, M, Tyler, D, Mantyh, C, Shellito, Paul Clarke, Chung, Daniel Chulyong, Clark, Jeffrey William, Jain, Rakesh K

Volltext

The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery von Klos, Coen L, Shellito, Paul Clarke, Rattner, David William, Hodin, Richard, Cusack, James C, Bordeianou, Liliana Grigorievna, Sylla, Patricia, Hong, Theodore Sunki, Blaszkowsky, Lawrence Scott, Ryan, Davis P, Lauwers, Gregory Y, Chang, Yu Chiao, Berger, David Lawrence

Volltext

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer von Xu, Lauren, Duda, Dan Gabriel, di Tomaso, E, Ancukiewicz, M, Chung, Daniel Chulyong, Lauwers, Gregory Y, Samuel, R, Shellito, Paul Clarke, Czito, B. G, Lin, P.-C, Poleski, M, Bentley, R, Clark, J. W, Willett, C. G, Jain, Rakesh K

Volltext